Radius Recycling Inc Stock Price, News & Analysis

Radius Health has sold its second oncology asset, RAD140, to Ellipses Pharma, allowing the molecule to progress without financial risk to Radius. This divestment reinforces Radius's focus on its core business in innovative endocrine therapeutics. RAD140, a selective androgen receptor modulator, demonstrated clinical activity in a Phase 1a study involving postmenopausal women with advanced breast cancer. Radius is set to receive royalties as the program advances under Ellipses Pharma's management.

Radius Health and Menarini Group announced the successful completion of enrollment in the Phase 3 EMERALD trial of elacestrant, an oral Selective Estrogen Receptor Degrader (SERD) targeting postmenopausal individuals with ER+/HER2- advanced breast cancer. The trial reached its goal of 466 patients, including 220 with ESR1 mutations. The independent data monitoring committee recommended the trial continues without modification after reviewing a futility analysis. Final results, focusing on progression-free survival, are expected in the latter half of 2021.

Radius Health announced reaching the target enrollment milestone in the Phase 3 EMERALD trial of elacestrant, aimed at treating advanced breast cancer. The trial enrolled 466 patients, with 220 (47%) having an ESR1 mutation. An independent data monitoring committee recommended continuing the trial without modification after a futility analysis. Results assessing progression-free survival are expected in the second half of 2021. Both Radius and Menarini Group expressed enthusiasm over this milestone and its implications for future regulatory submissions.

Radius Health, Inc. announced the immediate resignation of Chief Financial Officer Jose (Pepe) Carmona, who played a pivotal role in the company's transition to a commercial entity. Dan Dolan has been appointed as Principal Financial and Accounting Officer, while Jim Chopas continues as Controller. The company also introduced a new Capital, Strategy, and Transactions (CST) group to enhance financial management and investor relations. This strategic reorganization aims to support Radius's growth and operational efficiency in the biopharmaceutical sector.

Radius Health announced presentations on abaloparatide-SC at the ASBMR 2020 Annual Virtual Meeting from September 11-15, highlighting significant findings.

Dr. Charles Morris emphasized notable results from a histomorphometry study, indicating strong bone formation in postmenopausal women with osteoporosis after 3 months of treatment.

The data will include details from the Phase III study in Japan, confirming its efficacy in high-risk fracture osteoporosis patients.

Radius Health, Inc. (Nasdaq: RDUS) announced the completion of enrollment in its phase 3 'wearABLe' trial, assessing a novel transdermal abaloparatide patch for postmenopausal women with osteoporosis. Approximately 500 women were enrolled, exceeding the target of 474. The trial aims to evaluate the patch's efficacy compared to the subcutaneous TYMLOS injection over 12 months. The top-line data results are expected in Q4 2021. This innovative delivery method could offer a unique alternative for patients, marking a significant step in treating osteoporosis.

Radius Health, Inc. (Nasdaq: RDUS) is set to participate in two major virtual conferences in September 2020. The company will engage with investors at the Citi 15th Annual BioPharma Virtual Conference on September 9-10, followed by the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15. During the latter, Radius will provide a corporate update through a live fireside chat at 11:45 a.m. ET, accessible via their website. Additionally, their lead product, TYMLOS, is FDA-approved for treating postmenopausal women with osteoporosis.

Radius Health, Inc. (Nasdaq: RDUS) has appointed Sean Murphy to its Board of Directors. Murphy brings over 30 years of experience from Abbott Laboratories, where he led corporate business development. Chairman Owen Hughes stated that Murphy's integrity and industry expertise will enhance Radius's strategic direction. Murphy serves on several other boards, including Poseida Therapeutics and Immucor, and has advised numerous companies on strategy. The appointment aims to strengthen Radius's business model and drive growth in innovative endocrine therapeutics.

Radius Health reported U.S. net sales of $50 million for TYMLOS, a 22% increase year-over-year, in its second quarter ending June 30, 2020. The company anticipates completing ATOM Phase 3 enrollment this week. Radius entered an exclusive global license for elacestrant with Menarini, receiving $30 million upfront and potential milestone payments of up to $320 million. A net loss of $43.9 million was reported for Q2 2020, compared to $35.5 million the previous year. The company had $126.3 million in cash at the end of June 2020.